octreotide acetate omega solution
omega laboratories limited - octreotide (octreotide acetate) - solution - 200mcg - octreotide (octreotide acetate) 200mcg - miscellaneous therapeutic agents
octreotide
max health limited - octreotide acetate 0.112 mg/ml equivalent to octreotide 100 mcg/ml - solution for injection - 100 mcg/ml - active: octreotide acetate 0.112 mg/ml equivalent to octreotide 100 mcg/ml excipient: glycine hydrochloric acid mannitol water for injection - symptomatic control and reduction of growth hormone (gh) and igf-1 plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. octreotide treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.
octreotide
max health limited - octreotide acetate 0.056 mg/ml equivalent to octreotide 50 mcg/ml - solution for injection - 50 mcg/ml - active: octreotide acetate 0.056 mg/ml equivalent to octreotide 50 mcg/ml excipient: glycine hydrochloric acid mannitol water for injection - symptomatic control and reduction of growth hormone (gh) and igf-1 plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. octreotide treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.
octreotide
max health limited - octreotide acetate 0.56 mg/ml equivalent to octreotide 500 mcg/ml - solution for injection - 500 mcg/ml - active: octreotide acetate 0.56 mg/ml equivalent to octreotide 500 mcg/ml excipient: glycine hydrochloric acid mannitol water for injection - symptomatic control and reduction of growth hormone (gh) and igf-1 plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. octreotide treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.
octreotide depot octreotide (as acetate) 20 mg modified release injection vial plus diluent prefilled syringe composite pack
teva pharma australia pty ltd - octreotide, quantity: 20 mg - injection, modified release - excipient ingredients: polyglactin; mannitol - acromegaly for the symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment but who are adequately controlled on s.c. treatment with octreotide. octreotide depot is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,gastro-entero-pancreatic tumours for the relief of symptoms associated with the following functional tumours of the gastro-enteropancreatic endocrine system: ? carcinoid tumours with features of the carcinoid syndrome ? vasoactive intestinal peptide secreting tumours (vipomas) in patients who are adequately controlled on subcutaneous treatment with octreotide octreotide depot is not curative in these patients.,advanced neuroendocrine tumours of the midgut treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.
octreotide depot octreotide (as acetate) 30 mg modified release injection vial plus diluent prefilled syringe composite pack
teva pharma australia pty ltd - octreotide, quantity: 30 mg - injection, modified release - excipient ingredients: polyglactin; mannitol - acromegaly for the symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment but who are adequately controlled on s.c. treatment with octreotide. octreotide depot is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,gastro-entero-pancreatic tumours for the relief of symptoms associated with the following functional tumours of the gastro-enteropancreatic endocrine system: ? carcinoid tumours with features of the carcinoid syndrome ? vasoactive intestinal peptide secreting tumours (vipomas) in patients who are adequately controlled on subcutaneous treatment with octreotide octreotide depot is not curative in these patients.,advanced neuroendocrine tumours of the midgut treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.
octreotide depot octreotide (as acetate) 10 mg modified release injection vial plus diluent prefilled syringe composite pack
teva pharma australia pty ltd - octreotide, quantity: 10 mg - injection, modified release - excipient ingredients: polyglactin; mannitol - acromegaly for the symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment but who are adequately controlled on s.c. treatment with octreotide. octreotide depot is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,gastro-entero-pancreatic tumours for the relief of symptoms associated with the following functional tumours of the gastro-enteropancreatic endocrine system: ? carcinoid tumours with features of the carcinoid syndrome ? vasoactive intestinal peptide secreting tumours (vipomas) in patients who are adequately controlled on subcutaneous treatment with octreotide octreotide depot is not curative in these patients.,advanced neuroendocrine tumours of the midgut treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.
dbl octreotide injection octreotide (as acetate) 0.5mg/1ml injection solution vial
pfizer australia pty ltd - octreotide -
dbl octreotide injection octreotide (as acetate) 0.05mg/1ml injection solution vial
pfizer australia pty ltd - octreotide -
octreotide sun octreotide (as acetate) 50 microgram/1 ml solution for injection ampoule
sun pharma anz pty ltd - octreotide -